Consistently, the Epac1-selective inhibitor CE3F4 shortened the duration of the pacing-induced atrial fibrillation and reduced the incidence of sympathetic activation-induced ventricular arrhythmias, suggesting that Epac1 pharmacological inhibition was an effective strategy in the prevention of arrhythmia [78]. This evidence concerns the gene RAPGEF3 and atrial fibrillation.